Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Clinical Science (London, England : 1979)
|
March 4, 2006
Effects of blood pressure lowering and metabolic control on systolic left ventricular function in Type II diabetes mellitus
Niels H Andersen, Steen H Poulsen, Per L Poulsen, et al.
European Journal of Heart Failure
|
August 25, 2017
Inotropic myocardial reserve deficiency is the predominant feature of exercise haemodynamics in cardiac amyloidosis
Tor Skibsted Clemmensen, Henning Mølgaard, Jens Sörensen, et al.
Clinical Transplantation
|
May 24, 2020
Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial
Kaspar Broch, Einar Gude, Kristjan Karason, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|
July 22, 2024
Long-term follow-up of the randomized, prospective Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trial
Entela Bollano, Arne K Andreassen, Hans Eiskjaer, et al.
Clinical Transplantation
|
June 23, 2017
Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE)
Anne Relbo Authen, Ingelin Grov, Kristjan Karason, et al.
Clinical Transplantation
|
June 20, 2017
Donor-specific antibodies are associated with micro- and macrovascular coronary disease, restrictive myocardial damage, and poor outcome in heart-transplanted patients
Tor Skibsted Clemmensen, Pernille Koefoed-Nielsen, Lis-Ann Jensen, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation
|
April 13, 2016
Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial
Lars Gullestad, Hans Eiskjaer, Finn Gustafsson, et al.
American Journal of Physiology. Heart and Circulatory Physiology
|
January 19, 2010
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
Mads Halbirk, Helene Nørrelund, Niels Møller, et al.
ESC Heart Failure
|
February 2, 2022
Effect of implantable cardioverter-defibrillators in patients with non-ischaemic systolic heart failure and concurrent coronary atherosclerosis
Christina Byrne, Ole Ahlehoff, Marie Bayer Elming, et al.
European Journal of Heart Failure
|
June 27, 2018
The clinical outcome of LMNA missense mutations can be associated with the amount of mutated protein in the nuclear envelope
Rasha A Al-Saaidi, Torsten B Rasmussen, Rune I D Birkler, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Clinical Science (London, England : 1979)
|
March 4, 2006
Effects of blood pressure lowering and metabolic control on systolic left ventricular function in Type II diabetes mellitus
Niels H Andersen, Steen H Poulsen, Per L Poulsen, et al.
European Journal of Heart Failure
|
August 25, 2017
Inotropic myocardial reserve deficiency is the predominant feature of exercise haemodynamics in cardiac amyloidosis
Tor Skibsted Clemmensen, Henning Mølgaard, Jens Sörensen, et al.
Clinical Transplantation
|
May 24, 2020
Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial
Kaspar Broch, Einar Gude, Kristjan Karason, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|
July 22, 2024
Long-term follow-up of the randomized, prospective Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trial
Entela Bollano, Arne K Andreassen, Hans Eiskjaer, et al.
Clinical Transplantation
|
June 23, 2017
Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE)
Anne Relbo Authen, Ingelin Grov, Kristjan Karason, et al.
Clinical Transplantation
|
June 20, 2017
Donor-specific antibodies are associated with micro- and macrovascular coronary disease, restrictive myocardial damage, and poor outcome in heart-transplanted patients
Tor Skibsted Clemmensen, Pernille Koefoed-Nielsen, Lis-Ann Jensen, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation
|
April 13, 2016
Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial
Lars Gullestad, Hans Eiskjaer, Finn Gustafsson, et al.
American Journal of Physiology. Heart and Circulatory Physiology
|
January 19, 2010
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
Mads Halbirk, Helene Nørrelund, Niels Møller, et al.
ESC Heart Failure
|
February 2, 2022
Effect of implantable cardioverter-defibrillators in patients with non-ischaemic systolic heart failure and concurrent coronary atherosclerosis
Christina Byrne, Ole Ahlehoff, Marie Bayer Elming, et al.
European Journal of Heart Failure
|
June 27, 2018
The clinical outcome of LMNA missense mutations can be associated with the amount of mutated protein in the nuclear envelope
Rasha A Al-Saaidi, Torsten B Rasmussen, Rune I D Birkler, et al.
Page
of 5